BMY - Bristol-Myers Squibb Company

NYSE - NYSE Delayed Price. Currency in USD
49.60
+0.47 (+0.96%)
At close: 4:00PM EST

49.55 -0.05 (-0.10%)
After hours: 6:14PM EST

Stock chart is not supported by your current browser
Previous Close49.13
Open49.16
Bid49.34 x 800
Ask49.60 x 800
Day's Range48.47 - 49.88
52 Week Range44.30 - 70.05
Volume21,202,366
Avg. Volume12,649,950
Market Cap80.97B
Beta (3Y Monthly)1.12
PE Ratio (TTM)56.82
EPS (TTM)0.87
Earnings DateJan 24, 2019
Forward Dividend & Yield1.64 (3.42%)
Ex-Dividend Date2019-01-03
1y Target Est58.42
Trade prices are not sourced from all markets
  • GuruFocus.com3 hours ago

    The Stable Value Stock Is Built to Weather Market Storms

    It is hard to say anything about McKesson (MCK) that we have not said before -- it is a high-quality business with extremely cheap shares. McKesson stock is not just cheap -- it's incredibly cheap. McKesson, for example, benefited tremendously when billions of dollars worth of branded drugs lost their patents and went generic between 2009 and 2015.

  • What Kind Of Investor Owns Most Of Bristol-Myers Squibb Company (NYSE:BMY)?
    Simply Wall St.6 hours ago

    What Kind Of Investor Owns Most Of Bristol-Myers Squibb Company (NYSE:BMY)?

    The big shareholder groups in Bristol-Myers Squibb Company (NYSE:BMY) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own Read More...

  • Ligand (LGND) Takes a Hit on Citron's Negative Research Report
    Zacks7 hours ago

    Ligand (LGND) Takes a Hit on Citron's Negative Research Report

    Ligand (LGND) plunges as short-seller Citron Research questions the company's business prospects.

  • Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
    Zacks8 hours ago

    Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth

    Bristol-Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Why Bristol-Myers Squibb Stock Sank By 15.2% in 2018
    Motley Fool9 hours ago

    Why Bristol-Myers Squibb Stock Sank By 15.2% in 2018

    Bristol's inability to compete against Merck in front-line lung cancer weighed heavily on its shares last year.

  • Markit11 hours ago

    See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.

    # Bristol-Myers Squibb Co ### NYSE:BMY View full report here! ## Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for BMY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BMY. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $10.42 billion over the last one-month into ETFs that hold BMY are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. BMY credit default swap spreads are rising towards their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • The Zacks Analyst Blog Highlights: Procter & Gamble, NVIDIA, Bristol-Myers, Deere and Ecolab
    Zacks12 hours ago

    The Zacks Analyst Blog Highlights: Procter & Gamble, NVIDIA, Bristol-Myers, Deere and Ecolab

    The Zacks Analyst Blog Highlights: Procter & Gamble, NVIDIA, Bristol-Myers, Deere and Ecolab

  • Citron Says Ligand Has 80% Downside in Explosive Note
    Investopedia12 hours ago

    Citron Says Ligand Has 80% Downside in Explosive Note

    Citron Research, the activist short-seller headed by Andrew Left, has dug up some nasty evidence against Ligand Pharmaceuticals Inc. (LGND). In a 23-page report, Citron accused the San Diego-based biopharmaceutical company of misleading investors, adding that its future revenue calculations are a "pipe dream." The short seller then slapped a $35 price target on the stock, implying 80% downside from the report’s publication date. After failing to successfully develop its own drugs, Ligand switched its business model to focus on collecting royalties and milestone payments from compounds and intellectual property that it licenses to other drug developers.

  • Ligand Crashes To Nearly 2-Year Low After Short-Seller Bashes It
    Investor's Business Dailyyesterday

    Ligand Crashes To Nearly 2-Year Low After Short-Seller Bashes It

    Ligand Pharmaceuticals stock crashed to nearly a two-year low Wednesday after short-seller Citron Research slammed the biotech stock for having "80% downside from its current levels."

  • Takeda Wraps Its Shire Buyout, CEO Sees More Mergers Coming
    Investor's Business Dailyyesterday

    Takeda Wraps Its Shire Buyout, CEO Sees More Mergers Coming

    Takeda Pharmaceutical wrapped its $62 billion acquisition of Shire last week. CEO Christophe Weber predicts it won't be the last merger in the hot biopharma sector.

  • Top Analyst Reports for Procter & Gamble, NVIDIA & Bristol-Myers
    Zacksyesterday

    Top Analyst Reports for Procter & Gamble, NVIDIA & Bristol-Myers

    Top Analyst Reports for Procter & Gamble, NVIDIA & Bristol-Myers

  • Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line
    American City Business Journals2 days ago

    Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line

    The 17-year-old biotech company, a big player in antibody drug research and development, will focus its cash on a maturing pipeline of experimental drugs while letting go of some longtime employees.

  • Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter
    Investor's Business Daily2 days ago

    Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter

    Incyte stock launched Tuesday after an analyst suggested its portfolio of cancer treatments could net the biotech stock an acquisition offer. Biotech deals have been rampant this month.

  • Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer
    Zacks2 days ago

    Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer

    Bristol-Myers (BMY) gets EU approval for the immuno-oncology combination of Opdivo and low-dose Yervoy for the first-line treatment of patients with intermediate- and poor-risk advanced RCC.

  • How an East Bay cancer fighter — once kicked to the curb by Big Pharma — picked up its 4th drug approval
    American City Business Journals2 days ago

    How an East Bay cancer fighter — once kicked to the curb by Big Pharma — picked up its 4th drug approval

    Even in the days after Bristol-Myers Squibb Co. threw an experimental cancer drug back to Exelixis Inc. nearly a decade ago, there were signs of hope: strong signals from a broad trial that tested the drug across nine tumor types. One of those signals was confirmed Monday as the Food and Drug Administration approved that drug — branded as Cabometyx — as one of a handful of options for people with the most common kind of liver cancer. It is the fourth FDA approval of "cabo" for Alameda-based Exelixis (NASDAQ: EXEL), which eight years ago looked on the ropes when Bristol-Myers Squibb (NYSE: BMY) cut loose from a long-term partnership.

  • Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer
    Zacks2 days ago

    Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer

    Exelixis (EXEL) gets FDA approval for Cabometyx tablets for patients with hepatocellular carcinoma (liver cancer), who have been previously treated with Nexavar.

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.

    # Bristol-Myers Squibb Co ### NYSE:BMY View full report here! ## Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for BMY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BMY. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $15.76 billion over the last one-month into ETFs that hold BMY are among the highest of the last year, but the rate of growth is slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. BMY credit default swap spreads are at their highest levels for the past 3 years, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019
    Zacks3 days ago

    5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019

    Exelixis (EXEL) lead drug, Cabometyx continues to perform well.

  • Bristol-Myers Squibb (BMY) Stock Moves -0.04%: What You Should Know
    Zacks3 days ago

    Bristol-Myers Squibb (BMY) Stock Moves -0.04%: What You Should Know

    In the latest trading session, Bristol-Myers Squibb (BMY) closed at $47.97, marking a -0.04% move from the previous day.

  • Business Wire3 days ago

    European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

    First I-O/I-O combination regimen to receive European approval for previously untreated patients with advanced renal cell carcinoma

  • TheStreet.com3 days ago

    The Gold Rush of 2019

    Contagion The urge to merge is spreading. Two weeks ago, news broke that Bristol-Myers Squibb would spend $74 billion for Celgene . Then we heard that Eli Lilly would acquire Loxo Oncology for cash.

  • Benzinga4 days ago

    Barron's Picks And Pans: Amazon, Apple, Bristol-Myers, Starbucks And More

    This weekend's Barron's cover story reveals the results of the Barron's 2019 Investment Roundtable. "Barron's 2019 Investment Roundtable, Part 1" by Lauren R. Rublin reveals that, despite their worries about debt, disruption, interest rates and trade, members of the Barron's 2019 Roundtable see a decent year ahead for stocks. Find out why Amazon.com, Inc. (NASDAQ: AMZN) and many other picks are preferred by these experts.

  • 3 Top Dividend Stocks Selling at a Discount Right Now
    Motley Fool4 days ago

    3 Top Dividend Stocks Selling at a Discount Right Now

    Great yields. Great bargains. What more could you ask for?

  • Dealmaking surge confirms the stock market got far too ch...
    CNBC Videosyesterday

    Dealmaking surge confirms the stock market got far too ch...

    Jim Cramer explains why there's been more merger and acquisition activity in recent months and says it's "just getting started."